April 27, 2021 Dr. Ralph Baric is one of four professors at UNC-Chapel Hill newly inducted into the National Academy of Sciences — one of the highest distinctions for a scientist or engineer in the United States.
February 9, 2021 Using a novel in vivo research model containing human lung tissue, UNC Gillings School of Global Public Health and UNC School of Medicine scientists demonstrated that the experimental drug EIDD-2801 proved dramatically effective at preventing and treating SARS-CoV-2 infection.
January 21, 2021 In response to the COVID-19 pandemic, scientists at UNC teamed up to create the Rapidly Emerging Antiviral Drug Discovery Initiative (READDI) to not only combat SARS-CoV-2 but also future viral outbreaks.
January 19, 2021 While COVID-19 has shaken the world, it has also pushed society to be more innovative and creative — two attributes that have been essential to the success of researchers at UNC. Carolina students, faculty and staff are engaged in an abundance of projects, making UNC the most cited university in the United States for coronavirus research.
November 12, 2020 A new study published in Science confirms that the D614G spike mutation allows the coronavirus that causes COVID-19 to replicate faster, outcompete and transmit more easily between hosts compared to the original virus. However, the mutation that enabled this strain to spread so quickly around the globe may also make it more susceptible to a vaccine.
October 23, 2020 Living human lung air sacs in tiny dishes promise to accelerate COVID-19 research.
October 12, 2020 New research from the Baric Lab suggests that an emerging strain of coronavirus known as swine acute diarrhea syndrome coronavirus (SADS-CoV) may have the potential to spread to humans as well.
August 31, 2020 A new COVID-19 mouse model developed at the University of North Carolina at Chapel Hill captures many of the features of human disease and has helped advance a vaccine candidate to clinical trial.
August 10, 2020 The development of a safe and effective vaccine is a key step in ending the COVID-19 pandemic. A group of scientists now report that a leading candidate COVID-19 vaccine raises neutralizing antibodies and robustly protects non-human primates against SARS-CoV-2, the virus that causes COVID-19.
August 3, 2020 In an effort to further our understanding of how COVID-19 is spread, the National Science Foundation has funded a team of researchers at the Gillings School, led by Dr. Barbara Turpin, to study the SARS-CoV-2 virus' potential for aerosol transmission.
